#151345

Anti-Leu2 [C8/144B] mAb

Cat. #151345

Anti-Leu2 [C8/144B] mAb

Cat. #: 151345

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-4 weeks

Target: Leu2 (CD8)

Class: Monoclonal

Application: IHC ; IF ; IP ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Jacqueline Cordell

Institute: University of Oxford

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-Leu2 [C8/144B] mAb
  • Alternate name: CD8a Molecule; T-Lymphocyte Differentiation Antigen T8/Leu-2; CD8 Antigen; Alpha Polypeptide (P32); MAL; T-Cell Surface Glycoprotein CD8 Alpha Chain; Leu2 T-Lymphocyte Antigen; OKT8 T-Cell Antigen; T-Cell Antigen Leu2; T8 T-Cell Antigen; CD8a Antigen; Leu2; P32
  • Clone: C8/144B
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Application: IHC ; IF ; IP ; WB
  • Description: C8/144B can be used to detect these cells in tissue sections and also their neoplastic counterparts.
  • Immunogen: Synthetic peptide (the 13 C-terminal residues of the cytoplasmic domain of human CD8a)
  • Isotype: IgG1
  • Myeloma used: P3/NS1/1-Ag4.1

Target Details

  • Target: Leu2 (CD8)
  • Target background: CD8 is a T cell co-receptor that recognises, together with the T cell receptor, MHC class I molecules. CD8 is present on human suppressor/cytotoxic T cells which make up 30% of circulating T cells.

Applications

  • Application: IHC ; IF ; IP ; WB

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • van Gool et al. 2015. Clin Cancer Res. 21(14):3347-55. PMID: 25878334.
  • POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer.
  • Harlin et al. 2009. Cancer Res. 69(7):3077-85. PMID: 19293190.
  • Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment.
  • Sato et al. 2005. Proc Natl Acad Sci U S A. 102(51):18538-43. PMID: 16344461.
  • Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
  • Mason et al. 1992. J Clin Pathol. 45(12):1084-8. PMID: 1479035.
  • Immunohistological detection of human cytotoxic/suppressor T cells using antibodies to a CD8 peptide sequence.